Neurology® Podcast

1) Comparative effectiveness research and 2) ACGME proposals for work duty hours. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Michael Benatar interviews Dr. Jacqueline French about her paper on comparative effectiveness research. In the next segment, Dr. Ryan Overman is reading our e-Pearl of the week about Guillain-Barré-like syndrome with thallium poisoning. In the next part of the podcast Dr. Ted Burns interviews Dr. Lori Schuh about ACGME recommendations for work duty hours for our Lesson of the Week. The participants had nothing to disclose except Drs. French, Overman, and Burns. Dr. French has served on scientific advisory boards for UCB, Johnson & Johnson, Eisai Inc., Novartis, Valeant Pharmaceuticals International, Icagen, Inc., Ikano Therapeutics Inc., Sepracor Inc., and Marinus Pharmaceuticals, Inc.; has received funding for travel from UCB, Kyowa Hakko Kirin Pharma, Inc., Eisai Inc., Johnson & Johnson, Valeant Pharmaceuticals International, and GlaxoSmithKline; serves as an Associate Editor of Epilepsy Currents and Supplement Editor for Epileptic Disorders; estimates that 30% of her time is spent in outpatient epilepsy practice; receives research support from the Epilepsy Therapy Development Project, FACES, Johnson & Johnson, Eisai Inc., UCB, SK Bio-Pharmaceuticals, Valeant Pharmaceuticals International, Vertex Pharmaceuticals, Pfizer Inc, Merck Serono, the NIH (R01 NS053998-01A1 [coinvestigator]), and from the Epilepsy Research Foundation; and serves as President of the Epilepsy Study Consortium, which receives money from multiple pharmaceutical companies. A fixed 20% of her NYU salary is paid by the study consortium, some of which may come from consulting fees from GlaxoSmithKline, Pfizer Inc, UCB, Johnson & Johnson, Cyberonics, Inc., SCHWARZ PHARMA, Ortho-McNeil-Janssen Pharmaceuticals, Inc., Eisai Inc., Jazz Pharmaceuticals, Ovation Pharmaceuticals, Endo Pharmaceuticals, Bial Pharmaceuticals, NeuroVista Corporation, Valeant Pharmaceuticals International, Icagen, Inc., Supernus Pharmaceuticals, Inc., Ikano Therapeutics Inc., SK Bio-Pharmaceuticals, TaroPharma, NeuroTherapeutics Pharma, Inc., Sepracor Inc., and Novartis. Dr. Overman serves as Deputy Editor on the Neurology® Resident and Fellow Section editorial team and the Neurology® Podcast Committee.Dr. Burns receives a stipend as Podcast Editor for Neurology®, and performs EMG studies in his neuromuscular practice (30% effort).

1) Acute progressive neurologic decline and absence of mass lesion and 2) AAN.com and community features it provides. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Karen Roos interviews Drs. Jason Taub and Jeffrey Olson about their paper on acute progressive neurologic decline. In the next segment, Dr. Ryan Overman is reading our e-Pearl of the week about unilateral photophobia or phonophobia in cluster headache. In the next part of the podcast Dr. Ted Burns interviews Dr. Daniel Hoch and Jose Merino about AAN.com and the community features it provides for our Lesson of the Week. The participants had nothing to disclose except Drs. Roos, Olson, Overman, Burns, Hoch, and Jose Merino. Dr. Roos serves as Editor-in-Chief of Seminars in Neurology, received royalties for 4 published textbooks, received funding for traveling from the AAN and other universities, and gave expert testimony, but monies received were forwarded to the Department of Neurology, Indiana University School of Medicine.Dr. Olson serves on the Data Safety Monitoring Board for Monteris, Inc., and has funded clinical research for which he is the Emory PI by Wyeth, Myriad Genetics, Inc., and Baxter International Inc.; and receives research support from the NIH (UO1CA137433-01 [Site PI], R01 CA116174 [Co-I], R01 CA121320-01 [Co-I], and R21 CA141836 [PI]).Dr. Overman serves as Deputy Editor on the Neurology® Resident and Fellow Section editorial team and the Neurology® Podcast Committee.Dr. Burns receives a stipend as Podcast Editor for Neurology®, and performs EMG studies in his neuromuscular practice (30% effort).Dr. Hoch serves as an editorial board member of AAN.com, holds stock options in Merck Serono and Biogen Idec, and gave expert testimony in the trial for the State of Massachusetts, Essex County, 2008-2010.Jose Merino receives a stipend as Associate Editor for AAN.com, serves as an editorial board member of Stroke and receives salary support from NINDS contract with Suburban Hospital.

1) Multiple sclerosis: A meta-analytic approach 2) Ultrasound of peripheral nerves (Part 2). This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Mark Keegan interviews Dr. Maria Pia Sormani about her paper on multiple sclerosis: A meta-analytic approach. In the next segment, Dr. Jennifer Fugate is reading our e-Pearl of the week about Terson syndrome. In the next part of the podcast Dr. Mary Lussier interviews Dr. Michael Cartwright for part two on peripheral nerve ultrasound for our Lesson of the Week. In concluding, there is a brief statement where to find other up-to date patient information and current Patient Page. The participants had nothing to disclose except Drs. Sormani, Keegan, Fugate, and Cartwright.

1) Mild cognitive decline 2) Ultrasound of peripheral nerves (Part 1). This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Jeff Burns interviews Dr. Susan Landau about her paper on mild cognitive decline. In the next segment, Dr. Jennifer Fugate is reading our e-Pearl of the week about Doi's sign. In the next part of the podcast Dr. Mary Lussier interviews Dr. Michael Cartwright for part one on peripheral nerve ultrasound for our Lesson of the Week. The participants had nothing to disclose except Drs. Landau, Fugate, and Cartwright. Dr. Landau receives research support from the NIH (U01 AG024904 [Research specialist]).Dr. Fugate serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Cartwright receives research support from the NIH (1K23 N5062892-01A1) and has received speaker honoraria from AANEM and ASN annual meetings.

In this special podcast for the Neurology Journal, Dr. Ted M. Burns plays a dozen of the many interesting audio clips from Neurology Podcasts of the 2009-2010 academic year.

1) Diagnosis of acute ischemic stroke and 2) evidence-based medicine (Part 3). This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Brett Kissela interviews Dr. Peter Schellinger about his paper on diagnosis of acute ischemic stroke. In the next segment, Dr. Jennifer Fugate is reading our e-Pearl of the week about digiti quinti sign. In the next part of the podcast Dr. Michael Benatar interviews Dr. Mark Conaway for part three on evidence-based medicine probability, odds, and odds ratio for our Lesson of the Week. The participants had nothing to disclose except Drs. Kissela, Schellinger and Fugate. Dr. Kissela served on the scientific advisory board for Allergan, Inc in 2009; served as a consultant for Allergan for 2-day meeting in 2009; received honoraria from CME program and unrestricted educational grants; received research support from the NIH [R01 NS 30678], [N01 NS 081588], [1Ul1 RR026314] and received compensation for reviewing records for several medical/legal cases regarding stroke.Dr. Schellinger has served/serves on scientific advisory boards for Boehringer Ingelheim, ImaRx Therapeutics, Photothera, Cerevast, and CoAxia, Inc.; has served/serves on speakers' bureaus for and received funding for travel and speaker honoraria from Boehringer Ingelheim, Sanofi, ImaRx Therapeutics, Photothera, Cerevast, CoAxia, Inc., Solvay Pharmaceuticals, Inc., and GlaxoSmithKline; serves on editorial boards of Stroke and European Neurology; receives royalties from the publication of NeuroIntensiv (Springer, 2008) and received royalties from the publication of Stroke MRI (Steinkopff, 2004); has served as a consultant for CoAxia, Inc., Photothera, Cerevast, ImaRx, and Boehringer Ingelheim; and has provided expert testimony, affidavits, and acted as a witness or consultant in legal proceedings.Dr. Fugate serves on the editorial team for the Neurology® Resident and Fellow Section.

1) Depressive symptoms and risk of dementia and 2) Early history of the AAN. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. David Geldmacher interviews Dr. Jane Saczynski about her paper on depressive symptoms and risk of dementia. In the next segment, Dr. Jennifer Fugate is reading our e-Pearl of the week about wrong way eyes. In the next part of the podcast Dr. Ted Burns interviews Dr. Robert Joynt on the early history of the AAN for our Lesson of the Week. The participants had nothing to disclose except Drs. Fugate, Burns and Joynt. Dr. Geldmacher serves on editorial board of Brain Injury, has received speaker honoraria from Danville Regional Medical Center, Georgetown Medical School, University of Rochester, Cleveland Clinic, Kaiser Permanante and Academy for Healthcare Education, receives research support from Elan Corporation [PI], Eisai Inc. [PI], Medivation, Inc. [PI], Janssen [PI] and Novartis [PI].Dr. Fugate serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Burns receives a stipend as Podcast Editor for Neurology®, and performs EMG studies in his neuromuscular practice (30% effort).Dr. Joynt receives a stipend as Newsletter Editor for Neurology® and royalties from Archives of Neurology for published work.

1) Imaging in acute stroke and 2) conflicts of interest: A personal perspective. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Brett Kissela interviews Dr. Yves Samson about his paper on diffusion-weighted MR imaging in acute stroke. In the next segment, Dr. Ryan Overman is reading our e-Pearl of the week about posterior vermal split syndrome. In the next part of the podcast Dr. Matthew Wong interviews Dr. Joseph Martin for our Lesson of the Week about his paper on the pervasive influence of conflicts of interest. The participants had nothing to disclose except Drs. Kissela, Samson and Martin. Dr. Kissela served on the scientific advisory board for Allergan, Inc in 2009; served as a consultant for Allergan for 2-day meeting in 2009; received honoraria from CME program and unrestricted educational grants; received research support from the NIH [R01 NS 30678], [N01 NS 081588], [1Ul1 RR026314] and received compensation for reviewing records for several medical/legal cases regarding stroke. Dr. Samson is co-inventor of Neurinfarct software (Patent WO 2008/000973, issued 2008) currently owned by Intelligence in Medical Technologies, Paris; and holds stock in Intelligence in Medical Technologies. Dr. Martin has been on the Board of Directors at Baxter International for 8 years. For a short narrative describing this activity in greater detail, and the effect it had on Dr. Martin's activities, please see appendix e-1 at www.neurology.org

1) Restless legs syndrome and 2) evidence-based medicine (part 2). This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Aman Savani interviews Dr. Diego Garcia-Borreguero about his paper on restless legs syndrome. In the next segment, Dr. Ryan Overman is reading our e-Pearl of the week about fatal gastroenteritis. In the next part of the podcast Dr. Michael Benatar interviews Dr. Mark Conaway for part two on evidence-based medicine relative risk, relative risk reduction, absolute risk reduction, and NNT for our Lesson of the Week. You may also want to check out the other two-part series on evidence-based medicine where Dr. Michael Benatar interviewed Dr. Gary Gronseth for our March 30 and April 6 Lesson of the Week. The participants had nothing to disclose except Dr. Garcia-Borreguero. Dr. Garcia-Borreguero has served on scientific advisory boards for and received speaker honoraria from Boehringer Ingelheim, GlaxoSmithKline, UCB, Pfizer Inc, XenoPort, Inc., sanofi-aventis, Jazz Pharmaceuticals, and Merck & Co., Inc.

1) Embouchure dystonia and 2) progressive myoclonic encephalopathies. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Robert Pascuzzi interviews Dr. Bernhard Haslinger about his paper on embouchure dystonia. In the next segment, Dr. Ryan Overman is reading our e-Pearl of the week about the corneal reflex in stroke. In the next part of the podcast Dr. Alberto Espay interviews Dr. Berge Minassian for part 2 on progressive myoclonic encephalopathies for our Lesson of the Week. The participants had nothing to disclose except Drs. Haslinger, Pascuzzi and Espay. Dr. Haslinger serves on a scientific board for Merz Pharmaceuticals, LLC; has received funding from travel from Ipsen, Merz Pharmaceuticals, LLC, and Medtronic, Inc.; has received speaker honoraria from Novartis, GlaxoSmithKline, Desitin Pharmaceuticals, GmbH, Ipsen, and Allergan, Inc.; receives research support from Ipsen and from the German Research Foundation (DFG).Dr. Pascuzzi serves on the Board of Directors of the ABPN; serves on the Neurology RRC; served as immediate past Program Director for Neurology Residency Training at Indiana University; participates in multicenter clinical trials for a variety of neuromuscular disorders but receives no direct compensation; and gives lectures for the AAN and at multiple academic medical centers but does not received personal compensation.Dr. Espay received has personal compensation as a consultant for Boehringer Ingelheim; grant support from Codman; Medtronic, Inc; Allergan, Inc.; and CleveMed, and honoraria from UCB-SCHWARZ PHARMA AG; Medtronic, Inc. and Novartis.